Weight loss jab ‘significantly’ improves blood sugar in diabetics, study finds
The IndependentSign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Get our free Health Check email SIGN UP I would like to be emailed about offers, events and updates from The Independent. He said: “Our long-term analysis of semaglutide in a large and diverse cohort of patients with type 2 diabetes found a clinically relevant improvement in blood sugar control and weight loss after six months of treatment, comparable with that seen in randomised trials. This study suggests that improvements in blood sugars and weight loss can potentially be sustained in the longer term for adults with type 2 diabetes taking semaglutide as prescribed Esther Walden, Diabetes UK Prof Karasik added: “In this large real-world study, we were able to show durable reductions in HbA1c and body weight with emphasis on drug adherence. “Data are in line with results in randomised controlled trials and show the long-term stable benefit of once weekly semaglutide.” Esther Walden, deputy head of care at Diabetes UK, said: “This study suggests that improvements in blood sugars and weight loss can potentially be sustained in the longer term for adults with type 2 diabetes taking semaglutide as prescribed. “Drugs such as semaglutide are an important and valid weight management tool for those living with or at risk of type 2 diabetes, and people should be supported to find the approach that is most appropriate for them.” In August, Novo Nordisk published the findings of its own five-year study on Wegovy, known as the Select trial.